Journal of Clinical Lipidology
Volume 3, Issue 2 , Pages 70-77 , April 2009

Is HDL function as important as HDL quantity in the coronary artery disease risk assessment?

  • Sunita Dodani, MD, PhD

      Affiliations

    • Department of Internal Medicine, School of Medicine, Kansas University Medical Center, Wescoe Rm 4008 3901 Rainbow Blvd, MS 1022, Kansas City, KS 66160 USA
    • Corresponding Author InformationCorresponding author.
    • ,
  • Deanna G. Grice, BS

      Affiliations

    • School of Allied Health Sciences, Medical College of Georgia, Augusta, GA USA
    • ,
  • Sunil Joshi, PhD

      Affiliations

    • School of Nursing, Medical College of Georgia, Augusta, GA USA

Received 9 October 2008 ,Accepted 4 February 2009.

References 

  1. Okrainee K, Banerjee DK, Eisenberg MJ. Coronary artery disease in the developing world. Am Heart J. 2004;148:7–15
  2. Centers for Disease Control and Prevention. Heart Disease Death Rates, 2000–2004: Adults Age 35 Years and Older, By County. www.cdc.gov. c2008. Available at: http://www.cdc.gov/dhdsp/library/fs_heart_disease.htm.
  3. Levy D, Thom TJ. Death rates from coronary disease – progress and a puzzling paradox. N Engl J Med. 1998;339:915–917
  4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  5. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615–1622
  6. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360:7–22
  7. Kalhan R, Puthawala K, Agarwal S, Amini SB, Kalhan SC. Altered lipid profile, leptin, insulin, and anthropometry in offspring of South Asian immigrants in the United States. Metabolism. 2001;50:1197–1202
  8. Curb JD, Abbott RD, Rodriguez BL, et al. High density lipoprotein cholesterol and the risk of stroke in elderly men: the Honolulu heart program. Am J Epidemiol. 2004;160:150–157
  9. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels: The Framingham Study. JAMA. 1986;2835–2838
  10. Tulenko TN, Sumner AE. The physiology of lipoproteins. J Nucl Cardiol. 2002;9:638–649
  11. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–1389
  12. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001–1009
  13. Ridker PM, Danielson E, Fonseca FA, et al. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207
  14. Brewer HB. HDL metabolism and the role of HDL in the treatment of high risk patients with cardiovascular disease. Curr Cardiol Rep. 2007;9:486–492
  15. Cannon CP. High density lipoprotien cholesterol and residual cardiometabolic risk in metabolic syndrome. Clin Cornerstone. 2007;6:S14–23
  16. Navab M, Yu R, Gharavi N. High-density lipoprotein: antioxidant and anti-inflammatory properties. Curr Atheroscler Rep. 2007;9:244–248
  17. Libby P, Plutzky J. Inflamation in diabetes mellitus. Am J Cardiol. 2007;99(suppl.):27B–40B
  18. Watanbe J, Chou KJ, Liao JC, et al. Differential association of hemoglobin with pro-inflammatory high density lipoproteins in atherogenic/hyperlipidemic mice–a novel biomarker of atherosclerosis. J Biochem. 2007;282:23698–23707
  19. Barter PJ, Nicholls S, Rye K. Anti-inflammatory properties of HDL. Circ Res. 2004;95:764–772
  20. Radner M. Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest. 2006;116:3090–3100
  21. Navab M, Ananthramaiah GM, Reddy ST. The double jeopardy of HDL. Ann Med. 2005;37:173–178
  22. Yancey PG, Bortnick AE, Kellner-Weibel G, et al. Importance of different pathways of cellular cholesterol efflux. Arterioscler Thomb Vasc Biol. 2003;712–719
  23. Ross R, Glomset JA. The pathogenesis of atherosclerosis (first of two parts). N Engl J Med. 1976;295:369–377
  24. Ross R, Glomset JA. The pathogenesis of atherosclerosis (second of two parts). N Engl J Med. 1976;295:420–425
  25. Rotllan N, Ribas V, Calpe-Berdiel L. Overexpression of human apolipoprotein A-II in transgenic mice does not impair macrophage–specific reverse cholesterol transport in vivo. Arterioscler Thromb Vasc Biol. 2005;25:e128–e132
  26. Movva R, Rader DJ. Laboratory assessment of HDL heterogeneity and function. Clin Chem. 2008;54:788–800
  27. Von Eckardstein A, Nofer JR, Assmann G. High density lipoproteins and arteriosclerosis role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol. 2001;21:13–27
  28. Norato GD, Pirillo A, Catapano AL. Modified HDL: biological and physiopathological consequences. Nutr Metab Cardiovasc Dis. 2006;16:371–386
  29. Kontush A, Chapman MJ. Antiatherogenic small, dense HDL-guardian angel of the arterial wall?. Nat Clin Pract Cardiovasc Med. 2006;3:144–153
  30. van der Steeg WA, Holme I, Boekholdt SM, et al. High density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk. J Am Coll Cardiol. 2008;51:634–642
  31. Sviridov D, Mukhamedova N, Remaley AT, Chin-Dusting J, Nestel P. Antiatherogenic functionality of high density lipoprotein: how much versus how good. J Atheroscler Thromb. 2008;15:52–62
  32. Ansell BJ, Fonarow GC, Fogelman AM. High-density lipoprotein: is it always atheroprotective?. Curr Atheroscler Rep. 2006;8:405–411
  33. Fogelman AM. When good cholesterol goes bad. Nat Med. 2004;10:902–903
  34. Dodani S, Kaur R, Mohammad N, et al. Can dysfunctional HDL explain excess risk of coronary artery diseases in south Asian immigrants?. Int J Cardiol. 2008;129:125–132
  35. Zheng L, Nukuna B, Brennan ML, et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest. 2004;114:529–541
  36. Navab M, Anantharamaiah GM, Reddy ST, et al. Human apolipoprotein A-I and A-I mimetic peptides: potential for atherosclerosis reversal. Curr Opin Lipidol. 2004;15:645–649
  37. Shao B, Oda MN, Oram JF, Heinecke JW. Myeloperoxidase an inflammatory enzyme for generating dysfunctional high density lipoprotein. Curr Opin Cardiol. 2006;21:322–328
  38. Navab M, Hama Y, Hough GP, Subbanagounder G, Reddy ST, Fogelman AM. A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J Lipid Res. 2001;42:1308–1317
  39. Ansell BJ, Navab N, Hama S. Inflammatory/anti-inflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation. 2003;108:2751–2756
  40. Ansell BJ, Fonarow GC, Navab M, Fogelman AM. Modifying the anti-inflammatory effects of high-density lipoprotein. Curr Atheroscler Rep. 2007;9:57–63
  41. Chan DC, Barrett PH, Watts GF. Lipoprotein transport in the metabolic syndrome: pathophysiological and interventional studies employing stable isotopy and modelling methods. Clin Sci (Lond). 2004;107:233–249
  42. Tall AR, Yvan-Charvet L, Wang N. The failure of torcetrapib: was it the molecule or the mechanism?. Arterioscler Thromb Vasc Biol. 2007;2:257–260
  43. Tall AR. CETP inhibitors to increase HDL cholesterol levels. N Engl J Med. 2007;356:1364–1366
  44. Brown BG, Zhao XQ. Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk. Am J Cardiol. 2008;101(8A):58B–62B

PII: S1933-2874(09)00076-2

doi: 10.1016/j.jacl.2009.02.001

Journal of Clinical Lipidology
Volume 3, Issue 2 , Pages 70-77 , April 2009

Article Tools

* Image Usage & Resolution